Use of the H 3 receptor antagonist radioligand [ 3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H 3 receptor antagonists

British Journal of Pharmacology

Volumn 157, Issue 1, 2009, Pages 139-149

  Miller, T R ^a   Milicic, I ^a   Bauch, J ^a   Du, J ^a   Surber, B ^a   Browman, K E ^a   Marsh, K ^a   Cowart, M ^a   Brioni, J D ^a   Esbenshade, T A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

3H A 349821; ABT 239; Five trial inhibitory avoidance; H 3 receptor antagonist radioligand; H 3 receptor; H 3 receptor antagonist; Histamine; Radiotracer; Receptor occupancy

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; A 349821; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; TRITIUM; UNCLASSIFIED DRUG; A349821; BIPHENYL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; COGNITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG PENETRATION; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OXYGEN AFFINITY; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; ANIMAL; AUTORADIOGRAPHY; AVOIDANCE BEHAVIOR; BINDING COMPETITION; BRAIN; CELL MEMBRANE; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; RADIOASSAY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; AVOIDANCE LEARNING; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; BRAIN; CELL MEMBRANE; CEREBELLUM; CEREBRAL CORTEX; COGNITION; HISTAMINE H3 ANTAGONISTS; MALE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, HISTAMINE H3; TISSUE DISTRIBUTION; TRITIUM;

EID: 67149101464     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00239.x     Document Type: Article

References (44)

1. 11C]benzyl]-morpholine: evaluation of a potential. PET ligand. Nucl. Med Biol 33: 801-810.
2. 3 receptor inverse agonists. J Med Chem 50: 5439-5448.
3. 3 antagonist. Br J Pharmacol 143: 649-661.
4. 3 receptor antagonist and serotonin reuptake inhibitor. Eur J Pharmacol 576: 43-54.
5. 3 receptor antagonist. Eur J Pharmacol 250: 147-152.
6. 3 receptor antagonists. Inflammation Res 57 (Suppl. 1): S01-S02.
7. Esbenshade TA, Hancock AA (2000). Characterization of histaminergic receptors. Curr Prot Pharmacol 1: 1.19.1-1.19.19.
8. 3 receptor antagonist. Biochem Pharmacol 68: 933-945.
9. 3 receptor antagonist with druglike properties. J Pharmacol Exp Ther 313: 165-175.
10. 3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154: 1166-1181.
11. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538-544.
12. Fox GB, Pan JB, Esbenshade TE, Bennani YL, Black LA, Faghih R et al. (2002a). Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 131: 151-161. (Pubitemid 34143166)
13. 3 receptor ligands in a new mouse dipsogenia model. Pharmacol Biochem Behav 72: 741-750.
14. 3 receptor antagonist. J Pharmacol Exp Ther 313: 176-190.
15. 3 receptor. Nucl Med Biol 34: 981-987.
16. Hume SP, Gunn RN, Jones T (1998). Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 25: 173-176.
17. Kapur S, Barlow K, VanderSpek SC, Javanmard M, Nobrega JN (2001). Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. Psychopharmacology 157: 168-171. (Pubitemid 32802128)
18. 3 receptor antagonists. J Pharmacol Exp Titer 325: 902-909.
19. 3 agonists on food and water intake and urine flow in Wistar rats. Brain Res 793: 279-288.
20. 3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors. Neuropharmacology 51: 168-172.
21. Li Y, Hill G, Wong H, Kelly N, Ward K, Pierdomenico M et al. (2003). Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J Pharmacol Exp Ther 305: 86-96. (Pubitemid 36373838)
22. 3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321: 1032-1045.
23. 3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem Pharmacol 73: 1182-1194.
24. 3 receptor antagonists thioperamide and clobenpropit in rat and mouse, determined with ex vivo [125]iodophenpropit binding. Brain Res 743: 178-183.
25. Panula P, Jin C, Karlstedt K, Bakker R (2009). Phylogeny, gene structure, expression, and signaling. In: Vohora D (ed.). The Third Histamine Receptor. CRC Press: Boca Raton, FL, pp. 83-101.
26. Passani MB, Blandina P, Browman KE, Fox GB (2009). Cognition functions, attention-deficit hyperactivity disorders, and Alzheimer's disease. In: Vohora D (ed.). The Third Histamine Receptor. CRC Press: Boca Raton, FL, pp. 213-239.
27. Paul SM (1979). Correlation between benzodiazepine receptor occupation and anticonvulsant effects of diazepam. Nature 281: 688-689.
28. 3 receptor and its gene transcripts in rat brain. Neuroscience 114: 173-193.
29. 3 receptors in rat brain areas. Neuroscience 52: 169-189.
30. Scheffel U, Kim S, Cline EJ, Kuhar MJ (1994). Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: in vivo studies with [125I]RTI-55. Synapse 16: 263-268. (Pubitemid 24111525)
31. Schotte A, de Bruyckere K, Janssen PFM, Leysen JE (1989). Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Res 500: 295-301. (Pubitemid 19257048)
32. Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993). Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631: 191-202. (Pubitemid 24009988)
33. Selbach O, Haas HL (2009). Histamine as neurotransmitter. In: Vohora D (ed.). The Third Histamine Receptor. CRC Press: Boca Raton, FL, pp. 31-79.
34. 3 receptor genomic expression in the cerebral cortex of spontaneously hypertensive rat. Cell MoI Biol 53: 45-50.
35. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
36. 2 receptors. J Pharmacol Exp Ther 266: 1374-1384.
37. 3 receptors by thioperamide and (R)-α- methylhistamine measured using histamine turnover and an ex vivo labeling technique. Biochem Pharmacol 44: 1261-1267.
38. 3 receptor antagonist: in vitro and in vivo studies. J Pharmacol Exp Ther 275: 598-604.
39. 3-receptors. Eur J Pharmacol 23: 89-98.
40. 3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 16: 967-985.
41. 3 receptor as potential SPECT ligands. Nucl Med Biol 26: 651-659.
42. 3 receptor. Bioorg Med Chem 7: 1761-1767.
43. 3 receptor Inverse agonist radioligand. Br J Pharmacol 148: 657-670.
44. 3 receptor ligands. J Pharmacol Exp Ther 289: 1151-1159.